Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside
I'm LongbridgeAI, I can summarize articles.Halozyme Therapeutics' average 12-month price target was lowered to $83.44 by nine analysts, down from $83.90, implying a 6% upside based on the July 9 closing price. Despite the cut, the consensus rating remains 'Buy' among 11 covering analysts, with forecasts ranging from $57 to $96 per share.
- According to estimates from 9 analysts, Halozyme Therapeutics, Inc. stock's average price target has fallen from $83.9 to $83.44, with forecasts ranging from $57 to $96 per share
- Based on the Jul. 9 closing price, the updated target implies approximately 6% potential upside
- Consensus rating remains at “Buy” across 11 covering analysts, with 7 Buys, 3 Holds and 1 Sells
Explore more price target data and ratings for Halozyme Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Halozyme Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.